---
title: "Beta‑caryophyllene improves blood pressure, ECG, and cardiometabolic markers in a rat metabolic sy"
id: "biorxiv-0-beta-caryophyllene-restores-blood-pressure-heart-rate-and-electrocardiographic"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-0-beta-caryophyllene-restores-blood-pressure-heart-rate-and-electrocardiographic"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1?rss=1"
published_at: "2026-09-15T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Beta‑caryophyllene improves blood pressure, ECG, and cardiometabolic markers in a rat metabolic sy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-0-beta-caryophyllene-restores-blood-pressure-heart-rate-and-electrocardiographic
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1?rss=1)
- **Published At:** 2026-09-15T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This preclinical study evaluated the dietary cannabinoid **beta‑caryophyllene (BCP)** for prevention and reversal of diet‑induced **metabolic syndrome** and associated cardiovascular dysfunction in Wistar rats. - Seventy‑two male rats were randomized into six groups: two normal diet controls (with and without BCP) and four groups exposed to a high‑fat high‑fructose diet (HF/HFD) to induce metabolic syndrome, with subsequent interventions including continued HF/HFD, HF/HFD + BCP (50 mg/kg p.o.), dietary withdrawal to normal diet, and normal diet + BCP. - Hemodynamics and electrocardiograms were recorded via telemetry in conscious animals. Plasma apolipoprotein‑B (Apo‑B) and C‑reactive protein (CRP) were measured by ELISA. Lipid profiles, oxidative stress markers (SOD, GSH, MDA, NO), leptin, and organ histopathology (heart, liver, pancreas) were assessed. - BCP given to normal‑diet rats lowered systolic and diastolic **blood pressure**, heart rate, and shortened PR interval versus untreated controls. - In HF/HFD rats, BCP reduced systolic blood pressure and heart rate versus untreated HF/HFD animals, raised **HDL‑cholesterol** and antioxidant indices (SOD, GSH), and lowered total cholesterol, **Apo‑B**, leptin, nitric oxide, and malondialdehyde. - BCP lowered triglycerides in one comparison and reduced **CRP** across groups. Structural distortion in heart, liver, and pancreas induced by HF/HFD was reversed by BCP treatment in this model. - Authors conclude BCP exerts **anti‑atherogenic, anti‑inflammatory, and antioxidant** effects that ameliorate diet‑induced metabolic syndrome and cardiovascular dysfunction, proposing incorporation of BCP‑rich functional foods as a low‑cost NCD prevention strategy. - The report is a preprint and has not undergone peer review; clinical translation, dosing, safety in humans, and long‑term outcomes were not reported in the source.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=TS0VhwXHde1BuQtvIpZlOgQOl6WjPf0RepvaSLq5HT8-1789491127.9008656-1.2.1.1-TLe_IpHN0.YtRZGlFEFivFcGm5bIGFwK7eimx.HuwRAak.vedzezwRh8uIY7HWyx) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # Beta-caryophyllene restores blood pressure, heart rate, and electrocardiographic alterations while mitigating cardiometabolic biomarkers in a rat model of metabolic syndrome: Implications for non-communicable disease prevention. [ View ORCID Profile](http://orcid.org/0000-0002-6825-298X)JolaOluwa Oluwatosin Yesufu, Benson Ekunola Olufemi, Abiodun Adegoke Adeyemi, Adesoji Adedipe Fasanmade doi: https://doi.org/10.64898/2026.09.09.750314 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. JolaOluwa Oluwatosin Yesufu 1 University of Ibadan College of Medicine; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=JolaOluwa%2B%2BOluwatosin%2BYesufu%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Yesufu%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AJolaOluwa%2B%2BOluwatosin%2BYesufu%2B) * [ORCID record for JolaOluwa Oluwatosin Yesufu](http://orcid.org/0000-0002-6825-298X "Open in new tab") * For correspondence: johlah18@gmail.com Benson Ekunola Olufemi 2 University of Ibadan Faculty of Veterinary Medicine; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Benson%2B%2BEkunola%2BOlufemi%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Olufemi%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ABenson%2B%2BEkunola%2BOlufemi%2B) Abiodun Adegoke Adeyemi 3 University of Ibadan Faculty of Pharmacy * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abiodun%2B%2BAdegoke%2BAdeyemi%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Adeyemi%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAbiodun%2B%2BAdegoke%2BAdeyemi%2B) Adesoji Adedipe Fasanmade 1 University of Ibadan College of Medicine; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Adesoji%2B%2BAdedipe%2BFasanmade%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Fasanmade%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAdesoji%2B%2BAdedipe%2BFasanmade%2B) * [Abstract](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5780827/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5780827/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5780827/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5780827/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Metabolic Syndrome (MS) is an escalating non-communicable disease (NCD) and public health crisis heavily driven by modern high-calorie dietary transitions. MS is closely linked to catastrophic cardiovascular dysfunction (CVD). Conventional CVD medications are frequently constrained by high financial costs, system-wide adverse effects, and poor population-level accessibility in lower-middle-income countries (LMICs). This underscores an urgent public health need to evaluate safe, scalable, and low-cost dietary nutraceuticals for primary prevention. This study evaluated the cardioprotective and preventative effects of Beta-caryophyllene (BCP)—an affordable, widely accessible, and GRAS-designated dietary cannabinoid—in a lifestyle-mimicking rodent model of MS. Methods: Seventy-two male Wistar rats (10 weeks old) were divided into six groups (n=12/group). Groups I and II served as controls given Normal Diet (ND) alone and ND+β-caryophyllene (50 mg/kg p.o.), respectively. Metabolic Syndrome was induced in Groups III–VI using a High-Fat High-Fructose Diet (HF/HFD) for 16 weeks. For the subsequent 4 weeks, Group III continued on HF/HFD, Group IV received HF/HFD + BCP (50 mg/kg p.o.), Group V underwent dietary withdrawal (returned to a normal diet [ND]), and Group VI received ND + BCP. Conscious hemodynamic variables and electrocardiograms (ECG) were recorded via telemetry. Plasma apolipoprotein-B (Apo-B) and C-reactive protein (CRP) were quantified using ELISA. Lipid profiles, oxidative stress parameters, and organ histopathology were evaluated using standard biochemical and staining methods, with data analysed using ANOVA at α = 0.05. Results: In Group II, BCP decreased SBP (145.00±12.13 vs 120.30±2.15 mmHg), DBP (105.70±10.80 vs 94.00±17.20 mmHg), heart rate (448.00±11.90 vs 280.00±18.70 beats/min), and PR-interval (49.50±3.53 vs 45.00±12.70 ms) compared with Group I. Group IV significantly decreased SBP (129.00±1.28 vs 125.5±11.1 mmHg) and heart rate (380.00±16.20 vs 351.00±3.00 beats/min) compared with Group III. Furthermore, BCP significantly increased HDL-cholesterol (10.80±1.70 vs 15.40±1.00 mg/dl), SOD (0.35±0.07 vs 0.76±0.30 U/mg protein), and GSH (1.64±0.02 vs 3.60±0.13 mM) in Group IV compared with Group III. Conversely, BCP significantly decreased total cholesterol (166±31.00 vs 113±18.50 mg/dl), Apo-B (26.70±1.68 vs 19.00±1.30 mg/dl), leptin (5.10±0.03 vs 2.18±0.01 ng/ml), NO (6.30±0.40 vs 4.30±2.61 μM), and malondialdehyde (11.80±4.10 vs 9.90±2.30 μM) in Group IV. BCP significantly decreased triglycerides (64.90±1.30 vs 55.90±1.30 mg/dl) in Group VI compared with Group IV, while lowering CRP across all groups. Distortion of the cytoarchitecture of the heart, liver, and pancreas observed in Group III was completely reversed by BCP treatment in Group IV. Conclusion: Beta-caryophyllene effectively ameliorates diet-induced metabolic syndrome and associated cardiovascular dysfunction via potent anti-atherogenic, anti-inflammatory, and antioxidant mechanisms. These findings suggest that integrating affordable, culturally accepted, BCP-rich indigenous functional ingredients into regional nutrition frameworks represents a highly scalable, low-cost public health strategy for global NCD prevention. Keywords: Cardiovascular dysfunction, Metabolic Syndrome, Beta-caryophyllene, High-fat-high-fructose diet, Public Health Nutrition, NCD Prevention. ### Competing Interest Statement The authors have declared no competing interest. Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.04.16.719020v2 "QINT, a novel simplified QF/QUAS expression system with integrated temporal expression control") Posted September 15, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.09.09.750314v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/09/15/2026.09.09.750314.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) Beta-caryophyllene restores blood pressure, heart rate, and electrocardiographic alterations while mitigating cardiometabolic biomarkers in a rat model of metabolic syndrome: Implications for non-communicable disease prevention. JolaOluwa Oluwatosin Yesufu, Benson Ekunola Olufemi, Abiodun Adegoke Adeyemi, Adesoji Adedipe Fasanmade bioRxiv 2026.09.09.750314; doi: https://doi.org/10.64898/2026.09.09.750314 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.09.750314v1%26text%3DBeta-caryophyllene%2520restores%2520blood%2520pressure%252C%2520heart%2520rate%252C%2520and%2520electrocardiographic%2520alterations%2520while%2520mitigating%2520cardiometabolic%2520biomarkers%2520in%2520a%2520rat%2520model%2520of%2520metabolic%2520syndrome%253A%2520Implications%2520for%2520non-communicable%2520disease%2520prevention. "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.09.750314v1%26t%3DBeta-caryophyllene%2520restores%2520blood%2520pressure%252C%2520heart%2520rate%252C%2520and%2520electrocardiographic%2520alterations%2520while%2520mitigating%2520cardiometabolic%2520biomarkers%2520in%2520a%2520rat%2520model%2520of%2520metabolic%2520syndrome%253A%2520Implications%2520for%2520non-communicable%2520disease%2520prevention. "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.09.750314v1%26title%3DBeta-caryophyllene%2520restores%2520blood%2520pressure%252C%2520heart%2520rate%252C%2520and%2520electrocardiographic%2520alterations%2520while%2520mitigating%2520cardiometabolic%2520biomarkers%2520in%2520a%2520rat%2520model%2520of%2520metabolic%2520syndrome%253A%2520Implications%2520for%2520non-communicable%2520disease%2520prevention.%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F
## Related Clinical Research

- [Electrophysiological substrate and rotor frequency drive antiarrhythmic drug response in paroxysma](https://medichelpline.com/clinical-feed/biorxiv-10-electrophysiological-dependent-antiarrhythmic-drug-response-in-population-based.md)
- [Retinal changes on OCT may predict atrial fibrillation risk years earlier](https://medichelpline.com/clinical-feed/medical-news-today-0-how-changes-in-the-eyes-may-help-spot-afib-risk-years-early.md)
- [N‑aldehyde–modified phosphatidylethanolamines (NAMPs) from lipid peroxidation inhibit efferocytosis](https://medichelpline.com/clinical-feed/biorxiv-17-n-aldehyde-modified-phosphatidylethanolamines-formed-by-lipid-peroxidation.md)
- [Early menopausal hormone therapy linked to lower cardiovascular disease risk, SWAN study analysis](https://medichelpline.com/clinical-feed/medical-news-today-0-start-menopausal-hormone-therapy-early-for-a-lower-heart-disease-risk-study.md)
- [Moderate-to-vigorous physical activity and reduced adiposity and obesity risk in older adults at h](https://medichelpline.com/clinical-feed/medrxiv-13-moderate-to-vigorous-physical-activity-age-dependent-adiposity-and-obesity-risk.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.